Quantifying Renal Allograft Loss following Early Antibody-Mediated Rejection

Unlike antibody-mediated rejection (AMR) with clinical features, it remains unclear whether subclinical AMR should be treated, as its effect on allograft loss is unknown. It is also uncertain if AMR’s effect is homogeneous across donor (deceased/live) and (HLA/ABO) antibody types. We compared 219 pa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Am J Transplant
Autores principales: Orandi, Babak J., Chow, Eric H. K., Hsu, Annie, Gupta, Natasha, Van Arendonk, Kyle J., Garonzik-Wang, Jacqueline M., Montgomery, John R., Wickliffe, Corey, Lonze, Bonnie E., Bagnasco, Serena M., Alachkar, Nada, Kraus, Edward S., Jackson, Annette M., Montgomery, Robert A., Segev, Dorry L.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4304875/
https://ncbi.nlm.nih.gov/pubmed/25611786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajt.12982
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares